Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
from NYT > Technology https://ift.tt/3imHC2y
How an Unproven Alzheimer’s Drug Got Approved
July 19, 2021